Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 52.52$. Average daily volumn in 3 months 2.54M. Market cap 127.39B



Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 51.01$. Total volume : 7.62M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price
51.01$
Change
0.98
Volume
7.62M

Previous Close50.03
Open50.31
Day Range50.17-51.01
Bid49.80 x 1.2k
Ask51.29 x 1.8k
Volume7.62M
Average Volume2.54M
Market Cap127.39B
Beta0.36
52 Week Range46.93-58.10
Trailing P/E18.42
Foward P/E11.41
Dividend (Yield %)3.42%
Ex-Dividend Date2022-05-26



Financial Details


According to Sanofi's financial reports the company's revenue in 2021 were 39.17B an increase( +5.41%) over the years 2020 revenue that were of 37.37B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 12.29B(-50%).


Loading ...



Organization

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
127.39B
Revenue:
39.17B
Total Assets:
120.24B
Total Cash:
10.1B


News about "Sanofi"

sanofi-launches-global-health-brand-with-non-profit-treatments-image

Sanofi launches global health brand with non-profit treatments

Source from : Reuters - 13 hours ago

French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its ...See details»


new-sanofi-brand-designed-to-broaden-access-to-medicines-image

New Sanofi brand designed to broaden access to medicines

Source from : The Pharma Letter - 8 hours ago

French pharma major Sanofi (Euronext: SAN) has launched a new non-profit project designed to help at-risk populations in the worldโ€™s least developed countries. The Sanofi Global Health initiative is ...See details»


why-sanofi-is-investing-in-health-care-ecosystems-image

Why Sanofi is investing in health care ecosystems

Source from : Devex - 9 hours ago

Sanofi's global health unit, launched in 2021, announced on Monday a new brand and fund that will be supporting its goal to bring 30 essential medicines to 40 lower-income countries.See details»


sanofi-global-health-unveils-new-brand-impact-for-distribution-of-30-medicines-in-low-income-countries-image

Sanofi Global Health unveils new brand Impact for distribution of 30 medicines in low-income countries

Source from : Daily - 10 hours ago

Considered essential by the World Health Organization, the medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.See details»


sanofi-global-health-unveils-new-nonprofit-impact-brand-image

Sanofi Global Health unveils new nonprofit Impact brand

Source from : PMLiVE - 10 hours ago

Sanofi Global Health has announced the launch of Impact, a nonprofit brand of standard of care medicines developed by Sanofi. Sanofi Global Health is a nonprofit unit within Sanofi, committed to ...See details»


sanofi-caps-out-of-pocket-insulin-cost-at-35-for-uninsured-us-patients-image

Sanofi caps out-of-pocket insulin cost at $35 for uninsured U.S. patients

Source from : Reuters on MSN.com - 5 days ago

French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over ...See details»


fda-halts-tests-of-sanofi-drug-acquired-in-37b-buyout-due-to-side-effects-image

FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects

Source from : BioPharma Dive - 4 days ago

Liver problems in trial volunteers led the agency to curtail studies of the drug, marking the second major setback related to Sanofiโ€™s acquisition of Principia Biopharma.See details»


sanofis-sny-studies-on-btk-inhibitor-put-on-hold-by-fda-image

Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA

Source from : YAHOO!Finance - 3 days ago

Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.See details»


liver-injury-leads-fda-to-pause-sanofis-tests-of-ms-drug-acquired-in-37b-deal-image

Liver injury leads FDA to pause Sanofiโ€™s tests of MS drug acquired in $3.7B deal

Source from : MedCity News - 3 days ago

The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. While U.S. tests are paused, Sanofi ...See details»


sanofis-flu-shots-licensed-approved-for-the-us-2022-2023-influenza-season-image

Sanofi's flu shots licensed & approved for the U.S. 2022-2023 influenza season

Source from : Seeking Alpha - 3 days ago

Sanofi (SNY) on Friday said the U.S. FDA had licensed and approved its influenza vaccines for use in the 2022-2023 flu season.The vaccines approved include SNY's ...See details»


how-is-the-market-feeling-about-sanofi-image

How Is The Market Feeling About Sanofi?

Source from : Benzinga.com - 3 days ago

Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% ...See details»


Sanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+

Source from : Yahoo - 3 days ago

6 Following this licensure, Sanofi will begin to ship their vaccines helping to ensure more people, including some of our most vulnerable population of 65 years and older, will be immunized with ...See details»


sanofis-tolebrutinib-trials-in-msmyasthenia-gravis-put-on-partial-hold-by-fda-after-cases-of-liver-damage-image

Sanofi's tolebrutinib trials in MS/myasthenia gravis put on partial hold by FDA after cases of liver damage

Source from : Seeking Alpha - 4 days ago

The U.S. Food and Drug Administration ((FDA)) placed phase 3 studies of Sanofi's (SNY)ย oral drug tolebrutinib in multiple sclerosis ((MS)) and myasthenia gravis on partial ...See details»


insulin-manufacturer-sanofi-agrees-to-cap-cost-at-35-a-month-image

Insulin manufacturer Sanofi agrees to cap cost at $35 a month

Source from : Albany Herald - 2 days ago

Ga., released the following statement in response to insulin manufacturer Sanofi announcing it will cap the cost of insulin ...See details»